According to CoinMeta, Minohua announced that its holding subsidiary, Xuancheng Minohua Pharmaceutical Co., Ltd., underwent an on-site inspection by the US regulatory authority FDA from June 22 to June 26, 2026. The product under inspection was the active pharmaceutical ingredient (API) of Tildronexin (tildipirosin). On November 4, 2026, Xuancheng Minohua received an on-site inspection report (EIR) issued by FDA, indicating that it had passed this on-site inspection. This is the first time that Xuancheng Minohua's Tildronexin API has passed an inspection by FDA, marking that its API quality management system is in line with international requirements.